<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086150</url>
  </required_header>
  <id_info>
    <org_study_id>ENDO</org_study_id>
    <nct_id>NCT01086150</nct_id>
  </id_info>
  <brief_title>Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy</brief_title>
  <official_title>Use of Topical Lidocaine (Lidoderm 5% Patch) to Reduce Pain in Patients With Diabetic Neuropathy: Does the Density and Subtype of Sodium Channels Affect Response?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albany Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Albany Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if an investigational drug known as the lidocaine 5%
      patch is safe and effective in reducing the symptoms of diabetic neuropathy, to examine how
      topical lidocaine affects the nerve endings, and to determine whether treatment with the
      lidocaine patch can prevent the potential progression to chronic diabetic neuropathy pain in
      subjects who did not report pain at the start of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Scores From Composite Visual Analog Scale</measure>
    <time_frame>baseline, 4 weeks</time_frame>
    <description>Scores range from 0 to 10 with higher scores indicating higher levels of pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Keratinocyte Immunoreactivity of Nav1.6, Nav1.7, CGRP</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Pixel intensity (0-256) of immunofluorescence for each individual biomarker.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Diabetic Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Healthy control patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects 18 to 70 years of age, non-diabetic with no nervous system disease. Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type I or Type II diabetes with painful diabetic neuropathy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>18 to 70 years old with significantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with non-painful diabetic peripheral neuropathy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>18-70 years of age with Type I or Type II diabetes with non-painful or insignificantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at baseline, 4 weeks, and end of study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skin biopsy</intervention_name>
    <description>Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.</description>
    <arm_group_label>Healthy control patients</arm_group_label>
    <arm_group_label>Type I or Type II diabetes with painful diabetic neuropathy</arm_group_label>
    <arm_group_label>patients with non-painful diabetic peripheral neuropathy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine 5% patches</intervention_name>
    <description>Subject will apply patches to affected area QD for 12 hours then remove.</description>
    <arm_group_label>Healthy control patients</arm_group_label>
    <arm_group_label>Type I or Type II diabetes with painful diabetic neuropathy</arm_group_label>
    <arm_group_label>patients with non-painful diabetic peripheral neuropathy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group 1: 18-70 years of age, non-diabetic with no nervous system disease (healthy
             control group)

          -  Group 2: 18-70 years of age with Type I or Type II diabetes with significantly painful
             diabetic neuropathy (VAS &gt; 40mm at Baseline)

          -  Group 3: 18-70 years of age with Type I or Type II diabetes with non- painful or
             insignificantly painful diabetic neuropathy (VAS &lt; 40mm at Baseline)

        Exclusion Criteria:

          -  History of clinically significant liver disease, serious peripheral vascular disease,
             a blood clotting disorder, or any other medical condition felt to be exclusionary by
             the investigator

          -  Allergy to lidocaine

          -  Unwillingness to sign informed consent or any other reasons for which the investigator
             feels the subject cannot complete the study

          -  Women who are pregnant, breastfeeding or trying to become pregnant

          -  History of slow-healing diabetic foot ulcers

          -  Current skin or soft tissue lesions on the foot that will interfere with application
             of the lidocaine patch and or skin biopsies

          -  Subjects taking Class I antiarrhythmics

          -  HgA1c &gt; 11%

          -  Active cancer within the previous two years except treated basal cell carcinoma of the
             skin

          -  Co-morbidities that can produce neuropathy

          -  Subjects taking sodium channel blockers within one week of study treatment and
             throughout the study

          -  Subjects taking any other experimental drugs within 30 days prior to Screening Visit
             (Visit 1)

          -  Application of lidocaine patch to either foot within two weeks of Screening Visit
             (Visit 1)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 11, 2010</study_first_submitted>
  <study_first_submitted_qc>March 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2010</study_first_posted>
  <results_first_submitted>May 27, 2020</results_first_submitted>
  <results_first_submitted_qc>May 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 11, 2020</results_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albany Medical College</investigator_affiliation>
    <investigator_full_name>Charles Argoff</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy Control Patients</title>
          <description>Subjects 18 to 70 years of age, non-diabetic with no nervous system disease. Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.
Skin biopsy: Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
Lidocaine 5% patches: Subject will apply patches to affected area QD for 12 hours then remove.</description>
        </group>
        <group group_id="P2">
          <title>Type I or Type II Diabetes With Painful Diabetic Neuropathy</title>
          <description>18 to 70 years old with significantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.
Skin biopsy: Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
Lidocaine 5% patches: Subject will apply patches to affected area QD for 12 hours then remove.</description>
        </group>
        <group group_id="P3">
          <title>Patients With Non-painful Diabetic Peripheral Neuropathy</title>
          <description>18-70 years of age with Type I or Type II diabetes with non-painful or insignificantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at baseline, 4 weeks, and end of study.
Skin biopsy: Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
Lidocaine 5% patches: Subject will apply patches to affected area QD for 12 hours then remove.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Control Patients</title>
          <description>Subjects 18 to 70 years of age, non-diabetic with no nervous system disease. Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.
Skin biopsy: Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
Lidocaine 5% patches: Subject will apply patches to affected area QD for 12 hours then remove.</description>
        </group>
        <group group_id="B2">
          <title>Type I or Type II Diabetes With Painful Diabetic Neuropathy</title>
          <description>18 to 70 years old with significantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.
Skin biopsy: Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
Lidocaine 5% patches: Subject will apply patches to affected area QD for 12 hours then remove.</description>
        </group>
        <group group_id="B3">
          <title>Patients With Non-painful Diabetic Peripheral Neuropathy</title>
          <description>18-70 years of age with Type I or Type II diabetes with non-painful or insignificantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at baseline, 4 weeks, and end of study.
Skin biopsy: Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
Lidocaine 5% patches: Subject will apply patches to affected area QD for 12 hours then remove.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Scores From Composite Visual Analog Scale</title>
        <description>Scores range from 0 to 10 with higher scores indicating higher levels of pain.</description>
        <time_frame>baseline, 4 weeks</time_frame>
        <population>Healthy controls were not assessed for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control Patients</title>
            <description>Subjects 18 to 70 years of age, non-diabetic with no nervous system disease. Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.
Skin biopsy: Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
Lidocaine 5% patches: Subject will apply patches to affected area QD for 12 hours then remove.</description>
          </group>
          <group group_id="O2">
            <title>Type I or Type II Diabetes With Painful Diabetic Neuropathy</title>
            <description>18 to 70 years old with significantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.
Skin biopsy: Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
Lidocaine 5% patches: Subject will apply patches to affected area QD for 12 hours then remove.</description>
          </group>
          <group group_id="O3">
            <title>Patients With Non-painful Diabetic Peripheral Neuropathy</title>
            <description>18-70 years of age with Type I or Type II diabetes with non-painful or insignificantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at baseline, 4 weeks, and end of study.
Skin biopsy: Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
Lidocaine 5% patches: Subject will apply patches to affected area QD for 12 hours then remove.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores From Composite Visual Analog Scale</title>
          <description>Scores range from 0 to 10 with higher scores indicating higher levels of pain.</description>
          <population>Healthy controls were not assessed for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="6.5" lower_limit="4.5" upper_limit="9"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4.5" lower_limit="0" upper_limit="8.9"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Keratinocyte Immunoreactivity of Nav1.6, Nav1.7, CGRP</title>
        <description>Pixel intensity (0-256) of immunofluorescence for each individual biomarker.</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control Patients</title>
            <description>Subjects 18 to 70 years of age, non-diabetic with no nervous system disease. Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.
Skin biopsy: Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
Lidocaine 5% patches: Subject will apply patches to affected area QD for 12 hours then remove.</description>
          </group>
          <group group_id="O2">
            <title>Type I or Type II Diabetes With Painful Diabetic Neuropathy</title>
            <description>18 to 70 years old with significantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.
Skin biopsy: Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
Lidocaine 5% patches: Subject will apply patches to affected area QD for 12 hours then remove.</description>
          </group>
          <group group_id="O3">
            <title>Patients With Non-painful Diabetic Peripheral Neuropathy</title>
            <description>18-70 years of age with Type I or Type II diabetes with non-painful or insignificantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at baseline, 4 weeks, and end of study.
Skin biopsy: Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
Lidocaine 5% patches: Subject will apply patches to affected area QD for 12 hours then remove.</description>
          </group>
        </group_list>
        <measure>
          <title>Keratinocyte Immunoreactivity of Nav1.6, Nav1.7, CGRP</title>
          <description>Pixel intensity (0-256) of immunofluorescence for each individual biomarker.</description>
          <units>Pixel intensity (0-256)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nav1.6-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2" lower_limit="63.54" upper_limit="127.38"/>
                    <measurement group_id="O2" value="101.4" lower_limit="64.69" upper_limit="135.5"/>
                    <measurement group_id="O3" value="87.9" lower_limit="49.3" upper_limit="126.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nav1.6-4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="49.19" upper_limit="132.37"/>
                    <measurement group_id="O2" value="90.7" lower_limit="60.85" upper_limit="134.63"/>
                    <measurement group_id="O3" value="90.8" lower_limit="60.38" upper_limit="148.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nav1.7-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5" lower_limit="30.84" upper_limit="73.33"/>
                    <measurement group_id="O2" value="59.6" lower_limit="39.41" upper_limit="87.53"/>
                    <measurement group_id="O3" value="54.3" lower_limit="40.66" upper_limit="66.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nav1.7-4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" lower_limit="39.82" upper_limit="85.83"/>
                    <measurement group_id="O2" value="51.5" lower_limit="30.3" upper_limit="81.35"/>
                    <measurement group_id="O3" value="54.7" lower_limit="34.43" upper_limit="77.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CGRP-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" lower_limit="22.37" upper_limit="32.83"/>
                    <measurement group_id="O2" value="38.5" lower_limit="27.49" upper_limit="68.14"/>
                    <measurement group_id="O3" value="29.5" lower_limit="19.51" upper_limit="39.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CGRP-4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" lower_limit="21.86" upper_limit="49.53"/>
                    <measurement group_id="O2" value="32.8" lower_limit="19.03" upper_limit="56.1"/>
                    <measurement group_id="O3" value="26.2" lower_limit="20.52" upper_limit="36.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Healthy Control Patients</title>
          <description>Subjects 18 to 70 years of age, non-diabetic with no nervous system disease. Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.
Skin biopsy: Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
Lidocaine 5% patches: Subject will apply patches to affected area QD for 12 hours then remove.</description>
        </group>
        <group group_id="E2">
          <title>Type I or Type II Diabetes With Painful Diabetic Neuropathy</title>
          <description>18 to 70 years old with significantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.
Skin biopsy: Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
Lidocaine 5% patches: Subject will apply patches to affected area QD for 12 hours then remove.</description>
        </group>
        <group group_id="E3">
          <title>Patients With Non-painful Diabetic Peripheral Neuropathy</title>
          <description>18-70 years of age with Type I or Type II diabetes with non-painful or insignificantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at baseline, 4 weeks, and end of study.
Skin biopsy: Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
Lidocaine 5% patches: Subject will apply patches to affected area QD for 12 hours then remove.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charles E. Argoff, MD</name_or_title>
      <organization>Albany Medical College</organization>
      <phone>518 262-0034</phone>
      <email>argoffc@mail.amc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

